| __timestamp | Corcept Therapeutics Incorporated | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 17986000 |
| Thursday, January 1, 2015 | 36949000 | 32480000 |
| Friday, January 1, 2016 | 45240000 | 68081000 |
| Sunday, January 1, 2017 | 62416000 | 169906000 |
| Monday, January 1, 2018 | 81289000 | 248932000 |
| Tuesday, January 1, 2019 | 100359000 | 354100000 |
| Wednesday, January 1, 2020 | 105326000 | 433300000 |
| Friday, January 1, 2021 | 122356000 | 583300000 |
| Saturday, January 1, 2022 | 152848000 | 752700000 |
| Sunday, January 1, 2023 | 184259000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Cracking the code
In the competitive landscape of biotechnology, managing operational costs is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Corcept Therapeutics Incorporated from 2014 to 2023. Over this period, Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing nearly 50 times from 2014 to 2023. In contrast, Corcept Therapeutics has experienced a more modest, yet significant, fivefold increase.
This trend highlights the differing strategies of these companies in navigating the biotech industry's challenges.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights